Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.
Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC
Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.
mNSCLC: Biomarker Testing and Patient Adherence to TKIs
A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.
EXCLAIM Cohort in mNSCLC: Treatment Selection and Management
In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.
EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC
Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort.
Efficacy Data From the EXCLAIM Cohort in mNSCLC
Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.
Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design
Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC.
2 Commerce Drive Cranbury, NJ 08512